Plasma Export Market Intelligence: India's 215 Suppliers Shipping to 90 Countries — TransData Nexus 2026

Q: Who are the top plasma exporters from India?

The top plasma exporters from India are: 1. ALBERT DAVID LTD — $924.7K (32.9% market share); 2. ALBERT DAVID LIMITED — $688.3K (24.5% market share); 3. PLASMAGEN BIOSCIENCES PRIVATE LIMITED — $363.1K (12.9% market share); 4. S S SERUMS — $105.7K (3.8% market share); 5. ADVY CHEMICAL PRIVATE LIMITED — $81.9K (2.9% market share). Together they account for 77.0% of India's total plasma export value.

Q: What is the total export value of plasma from India?

The total export value of plasma from India is $2.8M USD, recorded across 15,000 shipment transactions from 215 active exporters to 90 destination countries. The average shipment value is $187.

Q: Which countries import plasma from India?

India exports plasma to 90 countries worldwide. The top importing countries are: GUYANA (25.2% share, $708.3K), SUDAN (18.9% share, $532.1K), SOUTH AFRICA (12.9% share, $363.2K), MADAGASCAR (11.6% share, $327.3K), SINGAPORE (6.7% share, $188.2K). These five markets account for 75.4% of total export value.

Q: What is the HS code for plasma exports from India?

The primary HS code for plasma exports from India is 30029010. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of plasma exports from India?

The average unit price for plasma exports from India is $27.16 USD per unit, with prices ranging from $0.00 to $79993.95 depending on formulation, packaging, and order volume. The total market is valued at $2.8M across 15,000 shipments.

Q: Which ports handle plasma exports from India?

The primary ports for plasma exports from India are DELHI AIR (34.8% of shipments), SAHAR AIR (16.0% of shipments), SAHAR AIR CARGO ACC (INBOM4) (14.8% of shipments), DELHI AIR CARGO ACC (INDEL4) (8.8% of shipments), Bombay Air (3.6% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of plasma?

India is one of the world's leading exporters of plasma due to its large base of 215 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports plasma to 90 countries, demonstrating 46% global market coverage.

Q: What certifications do Indian plasma exporters need?

Indian plasma exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import plasma from India?

There are 740 registered buyers importing plasma from India, spread across 90 countries. The repeat buyer rate is 46.4%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top plasma supplier from India?

ALBERT DAVID LTD is the leading plasma exporter from India with a market share of 32.9% and total export value of $924.7K across 133 shipments. The top 5 suppliers together control 77.0% of total export value.

Suresh Sormare

Plasma

India Pharmaceutical Trade Intelligence

$2.8M215 Suppliers90 CountriesHS 30029010

ExportsIndia → GUYANA25.2%India → SUDAN18.9%

ImportsGERMANY → India$6.3M AUSTRALIA → India$883.6K

#1 Buyer: NEW GPC

Plasma Export Analysis | Transdata Nexus | TransData Nexus

How India Exports Plasma to the World

Between 2022 and 2026, India exported $2.8M worth of plasma across 15,000 verified shipments to 90 countries — covering 46% of world markets. The largest destination is GUYANA (25.2%). ALBERT DAVID LTD leads with a 32.9% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published April 2026·Updated March 2026·HS 30029010

Plasma export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Plasma export data snapshot — $2.8M · 215 exporters · 90 countriesTransData Nexus · Indian Customs Data

Top Plasma Exporters from India

215 active exporters · Ranked by export value

View all 215 →

Top Plasma Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	ALBERT DAVID LTD	$924.7K	133	4	32.9%
2	ALBERT DAVID LIMITED

Top Countries Importing Plasma from India

90 destination markets · Ranked by import value

All 90 countries →

Top Countries Importing Plasma from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	GUYANA	$708.3K	25.2%
2	SUDAN	$532.1K	18.9%
3	SOUTH AFRICA	$363.2K	12.9%
4	MADAGASCAR	$327.3K	11.6%
5	SINGAPORE	$188.2K	6.7%
6	UNITED STATES	$123.5K	4.4%
7	FINLAND	$75.9K	2.7%
8	GERMANY	$75.6K	2.7%
9	THAILAND	$52.3K	1.9%
10	PHILIPPINES	$51.8K	1.8%

GUYANA is India's largest plasma export destination, absorbing 25.2% of total exports worth $708.3K. The top 5 importing countries — GUYANA, SUDAN, SOUTH AFRICA, MADAGASCAR, SINGAPORE — together account for 75.4% of India's total plasma export value. The remaining 85 destination countries collectively receive the other 24.6%, indicating a broadly diversified export footprint across multiple regions.

Who Supplies Plasma to India?

60 origin countries · Total import value: $1.7B

India imports plasma from 60 countries with a combined import value of $1.7B. The largest supplier is SRI LANKA ($608.9M, 11 shipments), followed by UNITED STATES and TAIWAN. All values are from Indian Customs (DGFT) import records.

Countries Supplying Plasma to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	SRI LANKA	$608.9M	11	35.6%
2	UNITED STATES	$538.7M	2,091	31.5%
3	TAIWAN	$392.0M	22	22.9%
4	ISRAEL	$91.8M	27	5.4%
5	UGANDA	$50.8M	22	3.0%
6	MALAYSIA	$10.5M	59	0.6%
7	GERMANY	$6.3M	182	0.4%
8	NETHERLANDS	$5.9M	31	0.3%
9	VIETNAM	$1.7M	8	0.1%
10	AUSTRALIA	$883.6K	45	0.1%

Showing top 10 of 60 origin countries

SRI LANKA is the largest supplier of plasma to India, accounting for 35.6% of total import value. The top 5 origin countries — SRI LANKA, UNITED STATES, TAIWAN, ISRAEL, UGANDA — together supply 98.3% of India's plasma imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Plasma

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, the Food and Drug Administration (FDA) regulates plasma-derived products under the Center for Biologics Evaluation and Research (CBER). These products are subject to stringent approval processes to ensure safety, purity, and potency. The FDA's Orange Book, which lists approved drug products, does not include plasma products, as they are classified as biologics and are instead listed in the Purple Book. The Purple Book provides information on licensed biological products, including plasma derivatives. As of March 2026, there are no Abbreviated New Drug Applications (ANDAs) approved for plasma products, given their biological nature and the complex manufacturing processes involved. Import alerts related to plasma products are periodically issued by the FDA to address safety concerns, such as contamination or deviations from Good Manufacturing Practices (GMP). Indian exporters aiming to enter the U.S. market must navigate the Biologics License Application (BLA) pathway, which involves comprehensive clinical trials and adherence to FDA regulations. The presence of 215 active Indian exporters indicates a robust interest in international markets, including the U.S., necessitating compliance with these stringent regulatory requirements.

2EU & UK Regulatory Framework

In the European Union (EU) and the United Kingdom (UK), plasma-derived medicinal products are regulated by the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), respectively. Marketing authorization for these products requires a centralized procedure through the EMA, ensuring uniformity across EU member states. The EMA mandates compliance with Good Manufacturing Practice (GMP) guidelines, which include specific requirements for plasma-derived products to ensure safety and efficacy. Similarly, the MHRA oversees the authorization and regulation of plasma products in the UK, adhering to stringent GMP standards. Indian exporters targeting these markets must obtain marketing authorization from the EMA or MHRA and demonstrate compliance with GMP requirements. The significant export volumes to countries like Guyana and Sudan suggest potential for expansion into the EU and UK markets, provided regulatory approvals are secured.

3WHO Essential Medicines & Global Standards

The World Health Organization (WHO) includes certain plasma-derived products, such as human normal immunoglobulin, in its Model List of Essential Medicines, recognizing their critical role in healthcare. The inclusion of these products underscores their importance in treating various medical conditions. The WHO Prequalification Programme sets global standards for the quality, safety, and efficacy of medicinal products, including plasma derivatives. Compliance with pharmacopoeial standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is essential for ensuring product quality and facilitating international trade. Indian exporters must align their products with these standards to meet the requirements of diverse global markets.

4India Regulatory Classification

In India, the Central Drugs Standard Control Organization (CDSCO) classifies plasma-derived products under Schedule X of the Drugs and Cosmetics Act, indicating their status as prescription drugs with stringent regulatory controls. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines under the Drugs (Prices Control) Order (DPCO), 2013. As of November 2025, the NPPA fixed ceiling prices for various formulations, including human normal immunoglobulin solutions, to ensure affordability and accessibility. Manufacturers and exporters are required to comply with these pricing regulations and obtain No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT) for the export of plasma products, ensuring that domestic supply is not adversely affected.

5Patent & Exclusivity Status

Plasma-derived products are often protected by patents covering specific manufacturing processes or therapeutic applications. However, due to the complex nature of plasma products and the challenges associated with their replication, generic competition is limited. The absence of ANDAs for plasma products in the FDA's Orange Book reflects this reality. Indian exporters must be cognizant of existing patents and exclusivity periods in target markets to navigate potential intellectual property challenges effectively.

6Recent Industry Developments

In November 2025, the NPPA revised the ceiling prices of several key medicines under the DPCO, 2013, including human normal immunoglobulin solutions, to enhance affordability and accessibility. This revision underscores the Indian government's commitment to regulating drug prices and ensuring essential medicines are within reach for the population. Additionally, in October 2025, the NPPA fixed new ceiling prices for six scheduled formulations under the DPCO, 2013, reflecting ongoing efforts to control drug prices and maintain market stability. These regulatory actions have implications for exporters, who must adjust pricing strategies to comply with domestic regulations while remaining competitive in international markets.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Supply Chain Risk Assessment — Plasma

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, including plasma-derived products, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of these essential components are sourced from China, making the supply chain vulnerable to disruptions stemming from geopolitical tensions, trade restrictions, or quality control issues.

This dependency was highlighted in February 2025 when the FDA issued warning letters to API manufacturers in both India and China for significant deviations from current Good Manufacturing Practices (cGMP). Such regulatory actions underscore the risks associated with overreliance on external suppliers for critical raw materials.

2Supplier Concentration & Single-Source Risk

The export market for plasma products from India is notably concentrated. The top five exporters account for 77.0% of the total export value, with ALBERT DAVID LTD alone contributing 32.9%. This high level of supplier concentration poses a significant risk; any operational or financial issues within these key companies could disrupt the entire supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic production of APIs and reducing dependence on imports. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules used in common antibiotics, marking a step towards enhancing self-reliance in pharmaceutical manufacturing.

Access Complete Plasma Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 15,000 transactions across 90 markets.

Request Demo View Pricing

Frequently Asked Questions — Plasma Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top plasma exporters from India?

The leading plasma exporters from India are ALBERT DAVID LTD, ALBERT DAVID LIMITED, PLASMAGEN BIOSCIENCES PRIVATE LIMITED, and 12 others. ALBERT DAVID LTD leads with 32.9% market share ($924.7K). The top 5 suppliers together control 77.0% of total export value.

What is the total export value of plasma from India?

The total export value of plasma from India is $2.8M, recorded across 15,000 shipments from 215 active exporters to 90 countries. The average shipment value is $187.

Which countries import plasma from India?

India exports plasma to 90 countries. The top importing countries are GUYANA (25.2%), SUDAN (18.9%), SOUTH AFRICA (12.9%), MADAGASCAR (11.6%), SINGAPORE (6.7%), which together account for 75.4% of total export value.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Plasma

Plasma

How India Exports Plasma to the World

Top Plasma Exporters from India

Top Countries Importing Plasma from India

Who Supplies Plasma to India?

Quick Facts

Related Products

Related Analysis

Need Details?

Regulatory Landscape — Plasma

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Supply Chain Risk Assessment — Plasma

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Plasma Trade Intelligence

Frequently Asked Questions — Plasma Exports from India

Who are the top plasma exporters from India?

What is the total export value of plasma from India?

Which countries import plasma from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the HS code for plasma exports from India?

What is the average price of plasma exports from India?

Which ports handle plasma exports from India?

Why is India a leading exporter of plasma?

What certifications do Indian plasma exporters need?

How many buyers import plasma from India?

What is the market share of the top plasma exporter from India?

Analysis Methodology